Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Frenova Renal Research

Neither a doctor nor a teaching hospital

Research payments

$4,396,716

78 payments

Through program year 2025, Frenova Renal Research is reported as receiving $4,396,716 in research payments, across 78 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $71,176 4
2024 Research $1,213,723 17
2023 Research $1,088,739 17
2022 Research $1,397,050 15
2020 Research $626,028 25

Breakdown

Who paid Research payments · program years 2020–2025
  1. AstraZeneca Pharmaceuticals LP $3,612,589 41 payments
  2. OPKO Pharmaceuticals, LLC $626,028 25 payments
  3. Biogen, Inc. $104,805 8 payments
  4. Alexion Pharmaceuticals, Inc. $43,848 2 payments
  5. AstraZeneca UK Limited $9,446 2 payments
Studies the money was for Research payments · program years 2020–2025
  1. A Phase III Randomized Double-blind Placebo-controlled Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442 a Combination Product of Two Monoclonal Antibodies (AZD8895 and AZD1061) for Pre-exposure Prophylaxis of COVID-19 $3,242,418 27 payments
  2. Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI $626,028 25 payments
  3. Tracking treatment pathways in adult patients with hyperkalemia (TRACK) $278,887 6 payments
  4. A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON (FALCON) $63,235 5 payments
  5. A Randomized, Double Blind, Placebo Controlled, Multicenter, Parallel Group, Dose Ranging Study to Evaluate CIN 107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease $49,909 3 payments
  6. Phase 2 Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) $43,848 2 payments
  7. An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE) (EAGLE) $41,571 3 payments
  8. A Phase III Randomized Double-blind Placebo-controlled Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442 a Combination Product of Two Monoclonal Antibodies AZD8895 and AZD1061 for Post-exposure Prophylaxis of COVID-19 $39,495 4 payments
  9. A Phase 2a Randomized Double blind Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI3506 in Subjects with Diabetic Kidney Disease $11,326 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record